Brief: Ocugen Announces First Patient Dosed In Phase 3 Trial For OCU400—First Gene Therapy In Phase 3 With A Broad Retinitis Pigmentosa Indication
20/06/2024 11:40
June 20 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 3
LIMELIGHT
CLINICAL TRIAL FOR OCU400—FIRST GENE THERAPY IN PHASE 3 WITH A
BROAD RETINITIS PIGMENTOSA INDICATION
* OCUGEN INC - OCU400 REMAINS ON TRACK FOR 2026 BLA AND MAA
APPROVAL TARGETS
Source text for Eikon: ID:nGNXbDHG
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))